Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2011 by AHS Cancer Control Alberta.
Recruitment status was:  Recruiting
Information provided by:
AHS Cancer Control Alberta Identifier:
First received: September 8, 2005
Last updated: January 18, 2012
Last verified: September 2011
A study of pharmacokinetics of daily intravenous busulfan

Condition Intervention
Hematologic Malignancy
Drug: intravenous busulfan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • pharmacokinetic data

Estimated Enrollment: 200
Study Start Date: January 1998
Estimated Study Completion Date: December 2010
Detailed Description:
A study of pharmacokinetics of daily intravenous busulfan

Ages Eligible for Study:   up to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients undergoing transplantation

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00156858

Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Rachel Syme, PhD   
Sub-Investigator: Chris Brown         
Sub-Investigator: Ron Anderson         
Principal Investigator: James Russell         
Sub-Investigator: Victor Lewis         
Sponsors and Collaborators
Alberta Health Services
Principal Investigator: James Russell, FRCp Alberta Cancerboard
  More Information Identifier: NCT00156858     History of Changes
Other Study ID Numbers: 10156
Study First Received: September 8, 2005
Last Updated: January 18, 2012

Keywords provided by AHS Cancer Control Alberta:

Additional relevant MeSH terms:
Fludarabine phosphate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Alkylating Agents
Antineoplastic Agents, Alkylating
Myeloablative Agonists processed this record on May 22, 2017